Fecal calprotectin for the prediction of small-bowel Crohn's disease by capsule endoscopy: A systematic review and meta-analysis

European Journal of Gastroenterology and Hepatology

Volumn 28, Issue 10, 2016, Pages 1137-1144

  Kopylov, Uri ^a   Yung, Diana E ^c   Engel, Tal ^a   Avni, Tomer ^b   Battat, Robert ^d   Ben Horin, Shomron ^a   Plevris, John N ^c   Eliakim, Rami ^a   Koulaouzidis, Anastasios ^c  

^a SHEBA MEDICAL CENTER   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

^c ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^d MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

calprotectin; capsule endoscopy; Crohn's disease

Indexed keywords

CALGRANULIN; BIOLOGICAL MARKER;

ARTICLE; CAPSULE ENDOSCOPE; CAPSULE ENDOSCOPY; CROHN DISEASE; DIAGNOSTIC ACCURACY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FECES ANALYSIS; HUMAN; META ANALYSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SMALL INTESTINE DISEASE; SYSTEMATIC REVIEW; CHEMISTRY; FECES; METABOLISM; ODDS RATIO; PATHOLOGY; PROGNOSIS; REPRODUCIBILITY; SMALL INTESTINE;

BIOMARKERS; CAPSULE ENDOSCOPY; CROHN DISEASE; FECES; HUMANS; INTESTINE, SMALL; LEUKOCYTE L1 ANTIGEN COMPLEX; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REPRODUCIBILITY OF RESULTS;

EID: 84978485844     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0000000000000692     Document Type: Article

References (37)

1. Steinhardt HJ, Loeschke K, Kasper H, Holtermüller KH, Schäfer H. European Cooperative Crohn's Disease Study (ECCDS): Clinical features and natural history. Digestion 1985; 31:97-108.
2. Van Assche G, Dignass A, Panes J, Beaugerie L, Karagiannis J, Allez M, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. J Crohns Colitis 2010; 4:7-27.
3. Røseth AG, Fagerhol MK, Aadland E, Schjønsby H. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992; 27:793-798.
4. Schoepfer AM, Beglinger C, Straumann A, Trummler M, Vavricka SR, Bruegger LE, Seibold F. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 2010; 105:162-169.
5. Dolwani S, Metzner M, Wassell JJ, Yong A, Hawthorne AB. Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology. Aliment Pharmacol Ther 2004; 20:615-621.
6. Sipponen T, Savilahti E, Kolho KL, Nuutinen H, Turunen U, Färkkilä M. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: Correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis 2008; 14:40-46.
7. Ho GT, Lee HM, Brydon G, Ting T, Hare N, Drummond H, et al. Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis. Am J Gastroenterol 2009; 104:673-678.
8. Kallel L, Ayadi I, Matri S, Fekih M, Mahmoud NB, Feki M, et al. Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: A prospective study. Eur J Gastroenterol Hepatol 2010; 22:340-345.
9. Turner D, Leach ST, Mack D, Uusoue K, McLernon R, Hyams J, et al. Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: A prospective multicentre comparison of predicting outcomes and monitoring response. Gut 2010; 59:1207-1212.
10. Koulaouzidis A, Rondonotti E, Karargyris A. Small-bowel capsule endoscopy: A ten-point contemporary review. World J Gastroenterol 2013; 19:3726-3746.
11. Lobaton T, Lopez-Garcia A, Rodriguez-Moranta F, Ruiz A, Rodriguez L, Guardiola J. A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease. J Crohns Colitis 2013; 7:e641-e651.
12. Kopylov U, Rosenfeld G, Bressler B, Seidman E. Clinical utility of fecal biomarkers for the diagnosis and management of inflammatory bowel disease. Inflamm Bowel Dis 2014; 20:742-756.
13. Kopylov U, Yablecovitch D, Lahat A, Neuman S, Levhar N, Greener T, et al. Detection of small bowel mucosal healing and deep remission in patients with known small bowel Crohn's disease using biomarkers, capsule endoscopy, and imaging. Am J Gastroenterol 2015; 110:1316-1323.
14. Lin JF, Chen JM, Zuo JH, Yu A, Xiao ZJ, Deng FH, et al. Meta-analysis: Fecal calprotectin for assessment of inflammatory bowel disease activity. Inflamm Bowel Dis 2014; 20:1407-1415.
15. Menees SB, Powell C, Kurlander J, Goel A, Chey WD. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol 2015; 110:444-454.
16. Mosli MH, Zou G, Garg SK, Feagan SG, MacDonald JK, Chande N, et al. C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: A systematic review and meta-analysis. Am J Gastroenterol 2015; 110:802-819.
17. Qiu Y, Mao R, Chen BL, He Y, Zeng ZR, Xue L, et al. Fecal calprotectin for evaluating postoperative recurrence of Crohn's disease: A metaanalysis of prospective studies. Inflamm Bowel Dis 2015; 21:315-322.
18. Sood R, Gracie DJ, Law GR, Ford AC. Systematic review with metaanalysis: The accuracy of diagnosing irritable bowel syndrome with symptoms, biomarkers and/or psychological markers. Aliment Pharmacol Ther 2015; 42:491-503.
19. Koulaouzidis A, Douglas S, Rogers MA, Arnott ID, Plevris JN. Fecal calprotectin: A selection tool for small bowel capsule endoscopy in suspected IBD with prior negative bi-directional endoscopy. Scand J Gastroenterol 2011; 46:561-566.
20. Gralnek IM, de Franchis R, Seidman E, Leighton JA, Legnani P, Lewis BS. Development of a capsule endoscopy scoring index for small bowel mucosal inflammatory change. Aliment Pharmacol Ther 2008; 27:146-154.
21. Koulaouzidis A, Sipponen T, Nemeth A, Makins R, Kopylov U, Nadler M, et al. Association between fecal calprotectin levels and small-bowel inflammation score in capsule endoscopy: A multicenter retrospective study. Dig Dis Sci 2016; 61:2033-2040.
22. Kopylov U, Nemeth A, Koulaouzidis A, Makins R, Wild G, Afif W, et al. Small bowel capsule endoscopy in the management of established Crohn's disease: Clinical impact, safety, and correlation with inflammatory biomarkers. Inflamm Bowel Dis 2015; 21:93-100.
23. Koulaouzidis A, Nemeth A, Johansson GW, Toth E. Dissecting Lewis score under the light of fecal calprotectin; an analysis of correlation of score components with calprotectin levels in capsule endoscopy. Ann Gastroenterol 2015; 28:259-264.
24. Jensen MD, Kjeldsen J, Nathan T. Fecal calprotectin is equally sensitive in Crohn's disease affecting the small bowel and colon. Scand J Gastroenterol 2011; 46:694-700.
25. Egea-Valenzuela J, Alberca-de-Las-Parras F, Carballo-Alvarez F. Fecal calprotectin as a biomarker of inflammatory lesions of the small bowel seen by videocapsule endoscopy. Rev Esp Enferm Dig 2015; 107:211-215.
26. Sipponen T, Haapamäki J, Savilahti E, Alfthan H, Hämäläinen E, Rautiainen H, et al. Fecal calprotectin and S100A12 have low utility in prediction of small bowel Crohn's disease detected by wireless capsule endoscopy. Scand J Gastroenterol 2012; 47:778-784.
27. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2 group. QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011; 155:529-536.
28. Olsen PA, Fossmark R, Qvigstad G. Fecal calprotectin in patients with suspected small bowel disease - A selection tool for small bowel capsule endoscopy? Scand J Gastroenterol 2015; 50:272-277.
29. Annese V, Daperno M, Rutter MD, Amiot A, Bossuyt P, East J, et al. European Crohn's and colitis organisation. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis 2013; 7:982-1018.
30. Kopylov U, Klang E, Ben-Horin S, Yablecovitch D, Lahat A, Neuman S, et al. Magnetic resonance enterography versus capsule endoscopy activity indices for quantification of small bowel inflammation in Crohn's disease. Therapeutic Advances in Gastroenterology 2016; 14:120-126.
31. Van Rheenen PF, van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: Diagnostic meta-analysis. BMJ 2010; 341:c3369.
32. Shaoul R, Sladek M, Turner D, Paeregaard A, Veres G, Wauters GV, et al. ESPGHAN Porto IBD Group. Limitations of fecal calprotectin at diagnosis in untreated pediatric Crohn's disease. Inflamm Bowel Dis 2012; 18:1493-1497.
33. Stawczyk-Eder K, Eder P, Lykowska-Szuber L, Krela-Kazmierczak I, Klimczak K, Szymczak A, et al. Is faecal calprotectin equally useful in all Crohn's disease locations? A prospective, comparative study. Arch Med Sci 2015; 11:353-361.
34. Koulaouzidis A, Douglas S, Plevris JN. Lewis score correlates more closely with fecal calprotectin than capsule endoscopy Crohn's disease activity index. Dig Dis Sci 2012; 57:987-993.
35. Gal E, Geller A, Fraser G, Levi Z, Niv Y. Assessment and validation of the new capsule endoscopy Crohn's disease activity index (CECDAI). Dig Dis Sci 2008; 53:1933-1937.
36. Niv Y, Ilani S, Levi Z, Hershkowitz M, Niv E, Fireman Z, et al. Validation of the capsule endoscopy Crohn's disease activity index (CECDAI or Niv score): A multicenter prospective study. Endoscopy 2012; 44:21-26.
37. Cotter J, dias de Castro F, Magalhaes J, Moreira MJ, Rosa B. Validation of the Lewis score for the evaluation of small-bowel Crohn's disease activity. Endoscopy 2015; 47:330-335.